Blephamide®
sulfacetamide 10% / prednisolone phosphate 0.23% · ophthalmic solution
Antibiotic/Steroid
Approved uses
Corticosteroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or a risk of bacterial ocular infection exists
Two drops in the affected eye(s) every four hours; no more than 20 mL initially
The antibiotic covers the infection risk the steroid would otherwise let run
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Known or suspected hypersensitivity to any ingredient, to other sulfonamides or to other corticosteroids (hypersensitivity to the antimicrobial component occurs at a higher rate than to the other components)
Sulfacetamide sodium 10% / prednisolone phosphate 0.23% ophthalmic solution, 5 mL or 10 mL in a 10 mL bottle
Sulfacetamide sodium is bacteriostatic: it restricts the synthesis of folic acid that susceptible bacteria require for growth, through competition with p-aminobenzoic acid. Prednisolone sodium phosphate is a corticosteroid; corticosteroids suppress the inflammatory response to a variety of agents and probably delay or slow healing.
Warnings & Precautions
- Not for injection into the eye: For ophthalmic use only.
- Ocular hypertension and glaucoma: Prolonged use of corticosteroids may result in ocular hypertension/glaucoma, with damage to the optic nerve and defects in visual acuity and fields of vision. If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Use corticosteroids with caution in the presence of glaucoma, and check intraocular pressure frequently.
- Posterior subcapsular cataract: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.
- Corneal or scleral thinning: Perforation has occurred with topical corticosteroids in diseases that thin the cornea or sclera.
- Masked or secondary infection: In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. Consider fungal infection of the cornea after prolonged corticosteroid dosing, and take fungal cultures when appropriate.
- Viral infection: Ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex), and their use in the treatment of herpes simplex requires great caution.
- Sulfonamide hypersensitivity: Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitizations may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of hypersensitivity or other serious reactions occur, discontinue use.
- Corticosteroid cross-sensitivity: Cross-sensitivity among corticosteroids has been demonstrated.
- Thimerosal sensitivity: Contains thimerosal 0.01%; do not use in patients sensitive to thimerosal or any other mercury-containing ingredient.
- Sulfonamide resistance: A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.
- Wound healing after cataract surgery: Corticosteroids may delay healing and increase the incidence of filtering blebs.
- Acute anterior uveitis: May occur in susceptible individuals, primarily Black patients.
- Mustard gas keratitis and Sjögren's keratoconjunctivitis: Topical corticosteroids are not effective in these conditions.
- Drug interactions: Incompatible with silver preparations. Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides, and the p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.
- Initial prescription and renewal: The initial prescription and renewal of the medication order beyond 20 mL should be made by a physician only after examination of the patient with the aid of magnification such as slit-lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should return for further evaluation.
- Darkened solution: Sulfonamide solutions darken on prolonged standing and exposure to heat and light. Do not use if solution has darkened; yellowing does not affect activity.
Common Side Effects
Reactions occurring most often from the antibacterial ingredient are allergic sensitizations, and sulfacetamide sodium may cause local irritation. Reactions due to the corticosteroid component, in decreasing order of frequency, are elevation of intraocular pressure with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.
Pregnancy: Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice, and in mice when given in doses 1 to 10 times the human ocular dose. When dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation, a significant increase in the incidence of cleft palate was observed in the fetuses. There are no adequate, well-controlled studies in pregnant women dosed with corticosteroids. Kernicterus may be precipitated in infants by sulfonamides given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects, and systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the medication.
Safety and effectiveness in pediatric patients below the age of 6 years have not been established.